U.S. markets open in 1 hour 13 minutes

Northwest Biotherapeutics, Inc. (NWBO)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
1.8500-0.4500 (-19.57%)
At close: 3:59PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close2.3000
Open2.4900
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range1.7000 - 2.5000
52 Week Range0.1400 - 2.5100
Volume23,335,402
Avg. Volume6,573,355
Market Cap1.355B
Beta (5Y Monthly)0.82
PE Ratio (TTM)N/A
EPS (TTM)-0.0870
Earnings DateAug 07, 2020 - Aug 11, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Northwest Biotherapeutics Announces Data Lock of Phase III Trial
    PR Newswire

    Northwest Biotherapeutics Announces Data Lock of Phase III Trial

    Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that the database for the Phase III trial of DCVax®-L for Gliobastoma has been locked.

  • Northwest Biotherapeutics Acquires Flaskworks
    PR Newswire

    Northwest Biotherapeutics Acquires Flaskworks

    Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that the Company has acquired Flaskworks, a company that has developed a breakthrough system to close and automate the manufacturing of cell therapy products such as DCVax®.

  • NW Bio Accelerating Sawston Plant Phase I Buildout
    PR Newswire

    NW Bio Accelerating Sawston Plant Phase I Buildout

    Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that the Company is pursuing an intensive program of manufacturing preparations and planning as the Company approaches top line data from its Phase III trial of DCVax®-L. A cornerstone of this expanding program is completion of the Phase I buildout of the Sawston, UK manufacturing facility.